Twist Bioscience Corporation TWST Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Bristol-Myers SquibbBMY

$15M—

IlluminaILMN

——

RevvityRVTY

——

AbbVieABBV

——

Other financials

Income statement

See full

Revenue$110.7M+19.3%

Gross profit$57.1M+24.1%

Operating income-$45.9M-10.4%

Net income-$44.0M-11.9%

EPS (diluted)-$0.71-7.6%

Balance sheet

See full

Cash & equivalents$124.9M-41.4%

Total debt$110.8M+16.3%

Total equity$455.1M+3.4%

Total assets$676.2M+13.5%

Cash flow

See full

Operating cash flow-$17.6M-35.2%

CapEx$7.9M+90.3%

Free cash flow-$25.4M-48.5%

Valuation

See full

Market cap$5.45B+24.4%

Enterprise value$5.44B+30.4%

P/S13.3×+0.7×

Profitability

See full

Gross margin52.1%+5.4pp

Operating margin-33.9%-9.9pp

Net margin-19.8%-7.7pp

FCF margin-23.2%+7.0pp

Returns & leverage

See full

Return on equity-18.2%-6.3pp

Debt / equity0.2×0.0×

Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Twist Bioscience Corporation’s 10-K, filed November 17, 2025, on SEC EDGAR. View the filing →

Ask your AI about Twist Bioscience Corporation's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Twist Bioscience Corporation's contingent consideration fair value adjustments?: Twist Bioscience Corporation (TWST) reported contingent consideration fair value adjustments of $0 in Q3 2025.
What is the long-term trend for Twist Bioscience Corporation's contingent consideration fair value adjustments?: Over 2 years (2023 to 2025), Twist Bioscience Corporation's contingent consideration fair value adjustments has grown at a -100.0% compound annual growth rate (CAGR), from -$5.91M to $0.